Sanaria’s malaria vaccine posted more positive clinical data, but a notable gap compared with results from U.S. studies calls for regimen improvements.
A Zika vaccine safe enough for women of childbearing age may still not be available before 2020, the World Health Organization estimated.
The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indications.…
Galena is finally getting some good news for its breast cancer vaccine NeuVax, as two trials combining it with Herceptin passed futility tests.
Novavax has started a new phase 2 trial on its key respiratory syncytial virus vaccine candidate
Keytruda is set for testing as part of a combo with Agenus’ cancer vaccine Prophage in glioblastoma.
Sanaria's malaria vaccine is one step closer to challenging GlaxoSmithKline's Mosquirix, thanks to data from a recent clinical trial.
Phase 2b data on Genocea's genital herpes vaccine is boosting confidence in the potential first-in-class shot.
The Army’s decision to transfer a Zika vaccine license to Sanofi has prompted some protest.
Add PaxVax to the list of companies vying to put the first Chikungunya vaccine on the market.
Bristol-Myers and Bavarian Nordic kicked off testing of the Big Pharma's checkpoint inhibitor Opdivo alongside the biotech's cancer vaccine CV301 in…